Skip to main content

Company News

February 28, 2024

The Rise of Multi-Drug Resistant Candidiasis in COVID-19 Patients

Data suggests that since the onset of the COVID-19 pandemic, there has been an increased prevalence of antimicrobial resistant infections and increases in healthcare-associated infections (HAIs). A recent study shows an alarming incidence of multidrug-resistant candidiasis in COVID-19 patients, which carries high morbidity and mortality rates. With this increasing prevalence of resistant infections, the utilization of surveillance tools such as whole genome sequencing (WGS) are critical in preventing the spread of these infections.
  • December 08, 2022

    Cell and Gene Therapies: bioMérieux partners with NecstGen

    bioMérieux and NecstGen, collaborate to accelerate the development of Cell and Gene Therapies (CGT) through the provision of ‘state of the art’ and rapid quality and safety testing technologies that will allow safe and effective advanced therapeutics production.
  • October 27, 2022

    20 years of collaboration in the fight against infectious diseases.

    For 20 years, bioMérieux and the Hospices Civils de Lyon (HCL) have been collaborating in an innovative public/private research partnership. Joined in 2016 by Claude Bernard Lyon 1 University, the three institutions are working to figure out the mechanisms of immunity in order to develop diagnostic tests.
  • September 01, 2022

    Florine, committed to the climate

    Team member testimonial from Florine, committed to the climate.
  • August 02, 2022

    Our EcoVadis Score Increases by 3 Points This Year !

    For the third consecutive year, we are awarded a Platinum medal, the highest level distinguishing bioMérieux as part of the Top 1%.

Follow us on Socials for more news!